James Armitage, M.D., receives national recognition

Armitage0609

Sandra Swain, M.D., past president of the American Society of Clinical Oncology (ASCO), at right, presents James Armitage, M.D., with the Special Achievement Award. (Photo courtesy of ASCO.)

Sandra Swain, M.D., past president of the American Society of Clinical Oncology (ASCO), at right, presents James Armitage, M.D., with the Special Achievement Award. (Photo courtesy of ASCO.) James Armitage, M.D., has received the 2014 American Society of Clinical Oncology’s Special Recognition Award for major accomplishments in the fields of oncology and hematology, as well as his many years of ASCO service.

The award, presented May 30, honors individuals for major contributions in areas of clinical oncology, cancer research, clinical trials, reimbursement, and patient advocacy activities, who have given long-term service to ASCO and to clinical oncology.

“It’s an honor to receive this award,” said Dr. Armitage, Joe Shapiro Professor of Internal Medicine in the UNMC Division of Oncology/Hematology. “My association with ASCO over the last 35 years has been a rewarding part of my career. ASCO has never wavered from its commitment to cancer patients in getting patients the best possible treatment and care.”

Dr. Armitage is globally recognized as a leading expert on non-Hodgkin lymphoma and played a critical role in advancing bone marrow transplantation.

Jeffrey P. Gold, M.D., UNMC chancellor, said the award is a tremendous honor for Dr. Armitage and great recognition for UNMC.

“He is an internationally recognized leader in cancer care. UNMC is proud to have him as a longstanding member of our faculty and in a leadership role in the Fred & Pamela Buffett Cancer Center.”

Lynell W. Klassen, M.D., Henry J. Lehnhoff Professor and chair of UNMC’s Department of Internal Medicine, said Dr. Armitage joins a prestigious group of recipients.

“Dr. Armitage is internationally acknowledged as one of the world’s foremost experts in the treatment of lymphoma. He established, at UNMC, the lymphoma program that grew into a world-renowned program. The award reflects the dedication, expertise and passion Dr. Armitage has for helping patients.

“With Jim receiving ASCO’s Special Recognition Award and with Julie Vose beginning her term as ASCO president, UNMC’s Division of Oncology/Hematology was recognized nationally at the world’s largest oncology meeting,” Dr. Klassen said.

Julie Vose, M.D., said Dr. Armitage has helped shape the progress of treatment and research in lymphoma and has been a key leader in ASCO.

“Dr. Armitage is a pioneer in hematology/oncology, a special teacher and mentor to all of us at UNMC for the last several decades, and he has built the foundation for our future at UNMC,” said Dr. Vose, Neumann M. and Mildred E. Harris Professorial Chair and chief of the division of oncology/hematology.

(Vicky Cerino, UNMC public relations, contributed to this story.)

Meet Dr. Armitage

James Armitage, M.D., developed and directed the bone marrow transplant programs at the University of Iowa and later at UNMC, where he also served as vice chair of internal medicine, chief of the section of oncology and hematology, chair of the Department of Internal Medicine, and dean of the College of Medicine.
The bone marrow transplant program at UNMC was one of the first to focus on autologous transplantation -— a process that involves storing a patient’s bone marrow stem cells so that the cells can be reintroduced after chemotherapy. The process helps patients tolerate higher doses of chemotherapy while reducing rates of complications, such as graft-versus-host disease, that often result when a patient receives donor bone marrow.
Dr. Armitage’s contributions span well beyond his work at UNMC and the University of Iowa. He has held many leadership roles at ASCO and other hematology and oncology associations, including ASCO president and president of the American Society for Blood and Marrow Transplantation.
He contributed to ASCO in many other capacities, including serving multiple terms on the board of directors and chairing the Cancer Education Committee, the Ethics Committee, and the Hematology-Oncology Task Force. Dr. Armitage is presently a member of the Journal of Clinical Oncology editorial board and is editor of The ASCO Post.

Comments are closed.